← All trials
NCT05257447
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 27, 2022
- Primary completion
- Mar 1, 2023
- Completion date
- Mar 1, 2023
- First posted
- Feb 25, 2022
- Last posted
- Apr 29, 2022
- Enrollment
- 15
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- The University of Texas, DallasLead sponsor
- Tufts UniversityCollaborator
- The University of Texas, DallasOverall official - principal investigator
- The University of Texas, DallasReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.